

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability under the Companies Ordinance)

(Stock Code: 00656)

PROGRESS UPDATE ON THE CONNECTED TRANSACTION IN RELATION TO PROPOSED SUBSCRIPTION OF A SHARES BY FOSUN GROUP

Reference is made to (i) the announcement of Fosun International Limited (the “**Company**”) dated 26 June 2009 in relation to, among others, a connected transaction regarding the proposed subscription of A Shares in Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“**Fosun Pharma**”) by Shanghai Fosun High Technology (Group) Co., Ltd. (“**Fosun Group**”) and (ii) the overseas regulatory announcement dated 5 May 2010 of the Company (collectively the “**Announcements**”). Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meaning as defined in the Announcements.

The board of directors of the Company is pleased to announce that the China Securities Regulatory Commission has approved the A Share Issue. The Company would like to update its shareholders and the potential investors on the following particulars in relation to the A Share Issue.

Issuer: Fosun Pharma

Type of Security: A Share of par value of RMB1.00 each

Subscription Price: As determined by the board of directors of the Fosun Pharma in consultation with the sponsor of the A Share Issue after a market price inquiry (市場詢價), the Subscription Price has been fixed at RMB20.60 per share

Number of A Shares to be issued: 31,820,000 A Shares

Fosun Group has subscribed for 3,182,000 A Shares, representing 10% of the aggregate number of A Shares under the A Share Issue at the Subscription Price of RMB65,549,200 (equivalent to approximately HK\$74,564,834). After completion of the A Share Issue, the equity interest in Fosun Pharma held by the Company (via Fosun Group) will decrease from 49.03% to 48.05% and Fosun Pharma will continue to be a subsidiary of the Company.

Upon completion of the share transfer agreement dated 5 June 2009 entered into between Fosun Group and Shanghai Fosun Pharmaceutical Development Company Limited on 15 October 2009, Fosun Pharma ceased to be a connected person of the Company.

The purpose of this announcement is to update the shareholders of the Company and potential investors on the progress of the proposed subscription of A Shares by Fosun Group.

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

Shanghai, the PRC, 5 May 2010

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetao and Mr. Wu Ping; the non-executive director is Mr. Liu Benren; and the independent non-executive directors are Dr. Chen Kaixian, Mr. Zhang Shengman and Mr. Andrew Y. Yan.

Unless otherwise stated, amount in RMB has been translated into HK\$ at exchange rate of HK\$1.00 to RMB0.87909 for illustration purposes only. No representation is made that any amount in RMB or HK\$ can be or could have been converted at the relevant dates at the above rates or any other rates at all.